Another face of placebo: The lessebo effect in Parkinson disease

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Neurology

• Publication date

  2014-04-22

• Fields of study

  Medicine

• Identifiers
  DOI 10.1212/WNL.0000000000000340PMID 24658930PMCID PMC4001195
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Study design features affecting outcome in antidepressant trials.

  2012cited by this paper
• Cochrane handbook for systematic reviews of interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration

  2011cited by this paper
• The Movement Disorder Society Evidence‐Based Medicine Review Update: Treatments for the non‐motor symptoms of Parkinson's disease

  2011cited by this paper
• Determination of minimal clinically important change in early and advanced Parkinson's disease

  2011cited by this paper
• Does inclusion of a placebo arm influence response to active antidepressant treatment in randomized controlled trials? Results from pooled and meta-analyses.

  2010cited by this paper
• Early (Uncomplicated) Parkinson's Disease

  2010cited by this paper
• Late (Complicated) Parkinson's Disease

  2010cited by this paper
• CSF Aβ42 and tau in Parkinson's disease with cognitive impairment

  2010cited by this paper
• Effects of expectation on placebo-induced dopamine release in Parkinson disease.

  2010cited by this paper
• The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration

  2009cited by this paper
• The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration

  2009cited by this paper
• Design makes a difference: a meta-analysis of antidepressant response rates in placebo-controlled versus comparator trials in late-life depression.

  2008cited by this paper
• Placebo response in Parkinson's disease: Comparisons among 11 trials covering medical and surgical interventions

  2008influential reference
• Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Scale presentation and clinimetric testing results

  2008influential reference
• Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society‐European Section (MDS‐ES). Part II: late (complicated) Parkinson's disease

  2006cited by this paper
• Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society-European Section (MDS-ES). Part II: late (complicated) Parkinson's disease.

  2006cited by this paper
• Practice Parameter: Treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology

  2006cited by this paper
• Minimal clinically important change on the unified Parkinson's disease rating scale

  2006cited by this paper
• Evidence‐based medical review update: Pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004

  2005cited by this paper
• Control group bias in randomized atypical antipsychotic medication trials for schizophrenia.

  2005cited by this paper
• Impact of placebo assignment in clinical trials of Parkinson's disease

  2003cited by this paper
• A comparison of antidepressant trials using active and inert placebos

  2003cited by this paper
• How should meta‐regression analyses be undertaken and interpreted?

  2002cited by this paper
• The Biochemical Bases for Reward

  2002cited by this paper
• Practice parameter: Initiation of treatment for Parkinson’s disease: An evidence-based review

  2002cited by this paper
• Growth in Paediatric Crohn’s Disease

  2002cited by this paper
• Expectation and Dopamine Release: Mechanism of the Placebo Effect in Parkinson's Disease

  2001cited by this paper
• Meta-analysis in clinical trials.

  1986cited by this paper

• Reconsidering Placebo Effects in Neuromodulation for Parkinson’s Disease: Lessons for Clinical Trials and Therapeutic Translation

  2026cites this paper
• Multi‐Target Repetitive Transcranial Magnetic Stimulation Improves Freezing of Gait in Parkinson's Disease: A Randomized Controlled Trial

  2025cites this paper
• Dilemmas in diagnosing Alzheimer's disease: The peril and promise of self-fulfilling prophecies

  2025cites this paper
• Placebo in Functional Neurological Disorders: Promise and Controversy

  2025cites this paper
• First phase 3 trial of GLP-1 receptor agonist for neurodegeneration.

  2025cites this paper
• Multi-omics characterization of improved cognitive functions in Parkinson’s disease patients after the combined metabolic activator treatment: a randomized, double-blinded, placebo-controlled phase II trial

  2025cites this paper
• Evidence and sources of placebo effects in transcranial direct current stimulation during a single session of visuospatial working memory practice

  2024cites this paper
• Placebo Effects and Neuromodulation: Ethical Considerations and Recommendations

  2023cites this paper
• The Lessebo Effect in Disease Modification Trials in Parkinson's Disease

  2023cites this paper
• Effects of Nabilone on Sleep Outcomes in Patients with Parkinson's Disease: A Post‐hoc Analysis of NMS‐Nab Study

  2022cites this paper
• Placebo and nocebo effects: from observation to harnessing and clinical application

  2022cites this paper
• Potential Protective Link Between Type I Diabetes and Parkinson's Disease Risk and Progression

  2022cites this paper
• Different symptomatic improvement pattern revealed by factor analysis between placebo response and response to Esketamine in treatment resistant depression

  2022cites this paper
• Methodological Considerations for Setting Up Deep Brain Stimulation Studies for New Indications

  2022cites this paper
• Sociability‐based fitness approach in Parkinson’s disease: Comparison with conventional rehabilitation

  2021cites this paper
• What is the role of placebo in neurotherapeutics?

  2021cites this paper
• The lessebo effect in randomized controlled trials of rituximab in patients with rheumatoid arthritis: a meta-analysis

  2021cites this paper
• The response to TNF blockers depending on their comparator in rheumatoid arthritis clinical trials: the lessebo effect, a meta-analysis.

  2021cites this paper
• Subjective cognition and mood in persistent chemotherapy-related cognitive impairment

  2021cites this paper
• Acute Exercise-Induced Set Shifting Benefits in Healthy Adults and Its Moderators: A Systematic Review and Meta-Analysis

  2021cites this paper
• Double‐Blind, Randomized, Placebo‐Controlled Trial of DA‐9701 in Parkinson's Disease: PASS‐GI Study

  2020cites this paper
• Nocebo and lessebo effects.

  2020cites this paper
• Deception and the ethics of placebo.

  2020cites this paper
• Nocebo and lessebo effects

  2020cites this paper
• The Adapted Resistance Training with Instability Randomized Controlled Trial for Gait Automaticity

  2020cites this paper
• Non‐Motor Symptoms in Parkinson's Disease are Reduced by Nabilone

  2020cites this paper
• Nocebo response in Parkinson's disease: A systematic review and meta-analysis.

  2019cites this paper
• Nicotinic treatment of post-chemotherapy subjective cognitive impairment: a pilot study

  2019cites this paper
• Clinical and pharmacokinetics equivalence of multiple doses of levodopa benserazide generic formulation vs the originator (Madopar)

  2019cites this paper
• Respuesta placebo en la enfermedad de Parkinson: una revisión teórica

  2018cites this paper
• Placebo responders and nonresponders: what's new?

  2018cites this paper
• Functional Movement Disorders and Placebo: A Brief Review of the Placebo Effect in Movement Disorders and Ethical Considerations for Placebo Therapy

  2018cites this paper
• Neurobiology of placebo effect in Parkinson's disease: What we have learned and where we are going

  2018cites this paper
• What influences placebo and nocebo responses in Parkinson's disease?

  2018cites this paper
• Deep brain stimulation improves restless legs syndrome in patients with Parkinson disease

  2018cites this paper
• Effects of deep brain stimulation on rest tremor progression in early stage Parkinson disease

  2018cites this paper
• Feasibility of a randomized single-blind crossover trial to assess the effects of the second-generation slow-release dopamine agonists pramipexole and ropinirole on cued recall memory in idiopathic mild or moderate Parkinson’s disease without cognitive impairment

  2017cites this paper
• Placebos in clinical trials: unravelling a complex phenomenon.

  2017cites this paper
• Probiotics Ingestion Does Not Directly Affect Thyroid Hormonal Parameters in Hypothyroid Patients on Levothyroxine Treatment

  2017cites this paper
• Challenges in detecting disease modification in Parkinson's disease clinical trials.

  2016cites this paper
• Dopamine D2 receptor gene variants and response to rasagiline in early Parkinson's disease: a pharmacogenetic study.

  2016cites this paper
• Predictors of the placebo response in clinical trials on Parkinson's disease: A meta-analysis.

  2016cites this paper
• Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial.

  2016cites this paper
• Factors influencing the outcome of deep brain stimulation: Placebo, nocebo, lessebo, and lesion effects

  2016cites this paper
• Impact of 6-month earlier versus postponed initiation of rotigotine on long-term outcome: post hoc analysis of patients with early Parkinson’s disease with mild symptom severity

  2015cites this paper
• Title Proceedings of the Second Annual Deep Brain Stimulation Think Tank : What ' s in the Pipeline Permalink

  2015cites this paper
• Association Between Placebo-Activated Neural Systems and Antidepressant Responses: Neurochemistry of Placebo Effects in Major Depression.

  2015cites this paper
• Recruitment strategies and patient selection in clinical trials for Parkinson's disease: Going viral and keeping science and ethics at the highest standards.

  2015cites this paper
• Proceedings of the Second Annual Deep Brain Stimulation Think Tank: What's in the Pipeline

  2015cites this paper
• Is Exenatide the Next Big Thing in Parkinson's Disease?

  2014cites this paper
• Disease-modifying therapy trials in PD: what are the issues?

  2014cites this paper
• Subthalamic nucleus‐deep brain stimulation for early motor complications in Parkinson's disease—the EARLYSTIM trial: Early is not always better

  2014cites this paper
• It's Not Just the Placebo Effect We Have to Worry About: Introducing Lessebo

  2014cites this paper
• Placebo: from belief to movement.

  2014cites this paper
• Myths and facts about the EARLYSTIM study

  2014cites this paper